Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced that its core product, the TROP2-directed antibody-drug conjugate $(ADC)$ sacituzumab tirumotecan (sac-TMT), in combination with the PD-L1 monoclonal antibody (mAb) tagitanlimab, has been granted Breakthrough Therapy Designation by the National Medical Products Administration in China. This designation is specifically for the first-line treatment of locally advanced, metastatic non-squamous non-small cell lung cancer (NSCLC) without actionable genomic alterations. This development marks a significant milestone for the company as it continues to advance its clinical research program, which includes multiple ongoing studies in collaboration with global partners.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief on June 11, 2025, and is solely responsible for the information contained therein.